Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
Santo Therapeutics, a Hangzhou-based in vivo gene therapy developer, announced it has received both Orphan...